Third Rock Portfolio Companies Innovate, Sometimes By Returning To The Roots Of Drug Discovery
Executive Summary
Third Rock Ventures has raised $1.3 billion by going all-in on early stage biotech with a homegrown company strategy that requires that its own people run many of its portfolio companies after launch. It’s hard to say definitely that the strategy is working, but its investors just re-upped for a new half-billion-dollar fund.